COMING: HIGHER OUT-OF-POCKET COSTS, SEPARATE SPECIALTY PHARMACY BENEFIT

A Zitter Group survey of key managed care decision makers, examining current and anticipated strategies for managing specialty pharmaceuticals, found that moving all specialty products into the drug benefit remains unlikely — regardless of how costs are shared.

Anticipated management strategies for specialty drugs*

*106 respondents. All percentages are rounded to the nearest whole number.

SOURCE: MANAGED CARE INJECTABLES INDEX, SPRING 2005, THE ZITTER GROUP, SAN FRANCISCO